Pfizer says kid-size doses of its COVID-19 vaccine are safe and nearly 91% effective at preventing infections in elementary school children.
The shots could begin in early November — with the first children in line fully protected by Christmas — if regulators give the go-ahead.
Full-strength Pfizer shots already are authorized for anyone 12 or older, but pediatricians and many parents are anxiously awaiting protection for younger children to stem rising infections from the extra-contagious delta variant and help keep kids in school. A Pfizer study tracked 2,268 kids in that age group who got two shots three weeks apart of either a placebo or the low-dose vaccine. Each dose was one-third the amount given to teens and adults.
That’s important information considering that hospitalizations of mostly unvaccinated children reached record levels last month.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Pfizer says COVID-19 vaccine more than 90% effective in kidsPfizer says kid-size doses of its COVID-19 vaccine are safe and nearly 91% effective at preventing symptomatic infections in elementary school children
Read more »
Pfizer says COVID-19 vaccine more than 90% effective in kidsKid-size doses of Pfizer’s COVID-19 vaccine appear safe and nearly 91% effective at preventing symptomatic infections in 5- to 11-year-olds, according to study details released Friday as the U.S. considers opening vaccinations to that age group. The shots could begin in early November — with the first children in line fully protected by Christmas — if regulators give the go-ahead. Details of Pfizer's study were posted online.
Read more »
Pfizer, BioNTech report high efficacy of COVID-19 booster shot in studyPfizer Inc and German partner BioNTech SE on Thursday said data from a Phase III trial demonstrated high efficacy of a booster dose of their COVID-19 vaccine against the virus, including the Delta variant.
Read more »
Pfizer Says Its Booster Shot Shows 95.6% Efficacy Against Covid-19I am a London-based reporter for Forbes covering breaking news. Previously, I have worked as a reporter for a specialist legal publication covering big data and as a freelance journalist and policy analyst covering science, tech and health. I have a master’s degree in Biological Natural Sciences and a master’s degree in the History and Philosophy of Science from the University of Cambridge. Follow me on Twitter theroberthart or email me at rhartforbes.com
Read more »
Pfizer-BioNTech Covid-19 Booster Shot Was 95.6% Effective in Large Trial, Companies SayThe study was carried out while the highly contagious Delta variant was prevalent, the companies said, suggesting the booster helps protect against the contagious strain.
Read more »
India celebrates 1 billion COVID-19 vaccine doses with song and danceIndia celebrated the milestone of administering one billion COVID-19 vaccine doses on Thursday, with the government promoting the achievement in song and video even as a recent drop in inoculations worries healthcare providers.
Read more »